HK Stock Market Move | Lithium battery concept drops, CALB (03931) fell 9% in the afternoon, Contemporary Amperex Technology (03750) dropped nearly 6%.
Under the concept of lithium batteries, as of the time of writing, Contemporary Amperex Technology (CATL) (03931) fell 8.6% to HK$25.21; and Contemporary Amperex Technology (Ningde) (03750) fell 5.82% to HK$502.
Under the concept of lithium batteries, as of the time of publication, CALB (03931) fell by 8.6%, to HK$25.21; Contemporary Amperex Technology (03750) fell by 5.82%, to HK$502.
On the news front, stimulated by the Zimbabwean ban, the main lithium carbonate futures contract rose by over 11% at the opening this morning. On February 25th, the Zimbabwean Ministry of Mines released a ban on lithium ore exports, aimed at strengthening mineral supervision and promoting the development of mineral processing. CITIC SEC pointed out that by 2025, 19% of China's imported lithium spodumene comes from Zimbabwe, and it is expected that by 2026, Zimbabwe's lithium resources will account for 12% of the global total. The country's ban on lithium ore exports is expected to lead to a short-term shortage of lithium carbonate supply in China, potentially driving up lithium prices significantly.
According to media reports, Google is heavily investing in "iron-air batteries". This new type of device, called "iron-air batteries", can provide stable power for up to 100 hours, compared to the current mainstream lithium batteries which can only maintain a limit of 4 to 8 hours. This technology significantly extends the lifespan of green energy facilities.
Related Articles

Chongqing Zhifei Biological Products (300122.SZ): HK.3-JN.1 COVID-19 mRNA vaccine approved for clinical trials.

Wuxi Delinhai Environmental Technology's net profit attributable to parent company for the year 2025 was 52.3075 million yuan, turning losses into gains year-on-year.

Citibank: TRIP.COM-S (09961) reports healthy fourth quarter performance. Revenue beats expectations but operating profit margin slightly underperforms.
Chongqing Zhifei Biological Products (300122.SZ): HK.3-JN.1 COVID-19 mRNA vaccine approved for clinical trials.

Wuxi Delinhai Environmental Technology's net profit attributable to parent company for the year 2025 was 52.3075 million yuan, turning losses into gains year-on-year.

Citibank: TRIP.COM-S (09961) reports healthy fourth quarter performance. Revenue beats expectations but operating profit margin slightly underperforms.

RECOMMEND

Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026

Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026

AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026


